Chemotherapy plus RA223 in the treatment of oat cell lung cancer

A. Lipton; H. A. Harvey; B. Walker; R. Dixon; D. Valdivia; S. Barnes; R. Gordon; D. White-Hershey; M. J. Bartholomew; N. Warzawski; C. E. Antle

doi:10.1097/00000421-198906000-00016

Chemotherapy plus RA223 in the treatment of oat cell lung cancer

A. Lipton
, H. A. Harvey
, B. Walker
, R. Dixon
, D. Valdivia
, S. Barnes
, R. Gordon
, D. White-Hershey
, M. J. Bartholomew
, N. Warzawski
, C. E. Antle

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

One hundred and one patients with oat (small) cell lung cancer have been treated with CAVE [Cytoxan, Adriamycin, Vicristine, and etoposide (VP-16)] chemotherapy ± RA233 (a platelet-inhibiting agent). There was no difference in disease-free interval, pattern of relapse, or survival between groups.

Original language	English (US)
Pages (from-to)	259-263
Number of pages	5
Journal	American Journal of Clinical Oncology: Cancer Clinical Trials
Volume	12
Issue number	3
DOIs	https://doi.org/10.1097/00000421-198906000-00016
State	Published - 1989

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

Access to Document

10.1097/00000421-198906000-00016

Cite this

@article{df96015a6be44c668d58670860015cea,

title = "Chemotherapy plus RA223 in the treatment of oat cell lung cancer",

abstract = "One hundred and one patients with oat (small) cell lung cancer have been treated with CAVE [Cytoxan, Adriamycin, Vicristine, and etoposide (VP-16)] chemotherapy ± RA233 (a platelet-inhibiting agent). There was no difference in disease-free interval, pattern of relapse, or survival between groups.",

author = "A. Lipton and Harvey, \{H. A.\} and B. Walker and R. Dixon and D. Valdivia and S. Barnes and R. Gordon and D. White-Hershey and Bartholomew, \{M. J.\} and N. Warzawski and Antle, \{C. E.\}",

year = "1989",

doi = "10.1097/00000421-198906000-00016",

language = "English (US)",

volume = "12",

pages = "259--263",

journal = "American Journal of Clinical Oncology: Cancer Clinical Trials",

issn = "0277-3732",

publisher = "Lippincott Williams and Wilkins",

number = "3",

}

TY - JOUR

T1 - Chemotherapy plus RA223 in the treatment of oat cell lung cancer

AU - Lipton, A.

AU - Harvey, H. A.

AU - Walker, B.

AU - Dixon, R.

AU - Valdivia, D.

AU - Barnes, S.

AU - Gordon, R.

AU - White-Hershey, D.

AU - Bartholomew, M. J.

AU - Warzawski, N.

AU - Antle, C. E.

PY - 1989

Y1 - 1989

N2 - One hundred and one patients with oat (small) cell lung cancer have been treated with CAVE [Cytoxan, Adriamycin, Vicristine, and etoposide (VP-16)] chemotherapy ± RA233 (a platelet-inhibiting agent). There was no difference in disease-free interval, pattern of relapse, or survival between groups.

AB - One hundred and one patients with oat (small) cell lung cancer have been treated with CAVE [Cytoxan, Adriamycin, Vicristine, and etoposide (VP-16)] chemotherapy ± RA233 (a platelet-inhibiting agent). There was no difference in disease-free interval, pattern of relapse, or survival between groups.

UR - https://www.scopus.com/pages/publications/0024391620

UR - https://www.scopus.com/pages/publications/0024391620#tab=citedBy

U2 - 10.1097/00000421-198906000-00016

DO - 10.1097/00000421-198906000-00016

M3 - Article

C2 - 2543207

AN - SCOPUS:0024391620

SN - 0277-3732

VL - 12

SP - 259

EP - 263

JO - American Journal of Clinical Oncology: Cancer Clinical Trials

JF - American Journal of Clinical Oncology: Cancer Clinical Trials

IS - 3

ER -

Chemotherapy plus RA223 in the treatment of oat cell lung cancer

Abstract

UN SDGs

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this